List of Aristada drug patents
Aristada is owned by Alkermes Inc.
Aristada contains Aripiprazole Lauroxil.
Aristada has a total of 13 drug patents out of which 0 drug patents have expired.
Aristada was authorised for market use on 05 October, 2015.
Aristada is available in suspension, extended release;intramuscular dosage forms.
Aristada can be used as treatment of schizophrenia, treatment of schizophrenia by rapid and continuous intramuscular injection, treatment of schizophrenia by rapid and continuous intramuscular injection; treatment of schizophrenia by rapid and continuous injection.
The generics of Aristada are possible to be released after 06 April, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10112903 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(7 years from now) | |
| US8431576 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Oct, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8796276 | ALKERMES INC | Heterocyclic compounds for the treatment of neurological and psychological disorders |
Jun, 2030
(7 years from now) | |
| US10226458 | ALKERMES INC | Pharmaceutical compositions comprising sorbitan esters |
Mar, 2032
(8 years from now) | |
| US9034867 | ALKERMES INC | Pharmaceutical compositions comprising sorbitan esters |
Nov, 2032
(9 years from now) | |
| US11097006 | ALKERMES INC | Pharmaceutical compositions having improved storage stability |
Oct, 2033
(10 years from now) | |
| US9193685 | ALKERMES INC | Pharmaceutical compositions having improved storage stability |
Oct, 2033
(10 years from now) | |
| US9452131 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(11 years from now) | |
| US10238651 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(11 years from now) | |
| US10813928 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(11 years from now) | |
| US9526726 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(11 years from now) | |
| US11406632 | ALKERMES INC | Aripiprazole formulations having increased injection speeds |
Mar, 2035
(11 years from now) | |
| US11273158 | ALKERMES INC | Aripiprazole dosing strategy |
Apr, 2039
(15 years from now) | |
Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient
Market Authorisation Date: 05 October, 2015
Treatment: Treatment of schizophrenia; Treatment of schizophrenia by rapid and continuous intramuscular injection; Treatment of schizophrenia by rapid and continuous injection
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ARISTADA family patents
49
United States
15
Japan
10
Australia
9
New Zealand
9
European Union
8
Canada
6
Israel
6
China
4
Spain
4
Russia
2
Croatia
2
Denmark
2
Cyprus
2
Portugal
2
Poland
2
Hong Kong
2
Slovenia
2
Mexico
2
Argentina
2
Brazil
2
RS
2
Hungary
2
Lithuania
1
IB
1
Saudi Arabia
1
Morocco
1
San Marino
1
Taiwan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic